Kellnerova Amends Autolus Therapeutics Stake Filing

TL;DR

Kellnerova's group updated their Autolus stake filing on 3/25/24. Watch for changes.

AI Summary

Renata Kellnerova, through PPF Biotech B.V. and PPF Group N.V., has amended their Schedule 13D filing for Autolus Therapeutics plc on March 25, 2024. This amendment likely reflects changes in their beneficial ownership or intentions regarding the company's securities.

Why It Matters

Changes in significant shareholder filings like this can signal shifts in control or investment strategy, potentially impacting the stock price and future corporate actions of Autolus Therapeutics.

Risk Assessment

Risk Level: medium — Amendments to 13D filings can indicate significant changes in a major shareholder's position or intentions, which could lead to market volatility.

Key Players & Entities

• Renata Kellnerova (person) — Filing party
• PPF Biotech B.V. (company) — Filing group member
• PPF Group N.V. (company) — Filing group member
• Autolus Therapeutics plc (company) — Subject company

FAQ

Key Financial Figures

• $0.000042 — nting one ordinary share, nominal value $0.000042 per share, and ordinary shares, nomina

Filing Documents

• ea0202429-13da9kell_autolus.htm (SC 13D/A) — 61KB
• 0001213900-24-025536.txt ( ) — 63KB

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer.

of Schedule 13D is supplemented and amended

Item 5 of Schedule 13D is supplemented and amended by the information below. The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. The percentage ownership of the ADSs representing Ordinary Shares is calculated based on 265,926,305 Ordinary Shares outstanding (including Ordinary Shares in the form of ADSs) as of March 20, 2024 (as set forth in the Issuer’s annual report on Form 10-K filed with the SEC on March 21, 2024). (a) Aggregate number and percentage of securities PPF Biotech is the owner of record of 14,612,275 Ordinary Shares represented by ADSs beneficially owned, or 5.5% of the Ordinary Shares of the Issuer. Each of the Reporting Persons, as a result of the relationships described in Item 2, may be deemed to directly or indirectly beneficially own the Ordinary Shares held by PPF Biotech. Each of the Reporting Persons disclaims beneficial ownership in all Ordinary Shares reported herein, except to the extent of its respective pecuniary interest therein. See also rows 11 and 13 of the cover pages to this Amendment No. 9 and Item 2 of Amendment No. 8 for the aggregate number of Ordinary Shares beneficially owned by each of the Reporting Persons. The ownership percentages reported in this Amendment No. 9 are based on 265,926,305 Ordinary Shares outstanding (including Ordinary Shares in the form of ADSs) as of March 21, 2024 (as set forth in the Issuer’s annual report on Form 10-K filed with the SEC on March 21, 2024). (b) Power to vote and dispose See rows 7 through 10 of the cover pages to, and Item 2 of, this Schedule 13D for the number of Ordinary Shares beneficially owned by each of the Reporting Persons as to which there is sole or shared power to vote or to direct the vote, and sole or shared power to dispose or to direct the disposition. (c) Transactions within the past 60 days The reported share amounts for the Reporting Persons reflect amounts as of the date hereof. Other than as

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: March 25, 2024 Renata Kellnerova By: /s/ Lubomír Král Name: Lubomír Král Title: Attorney-in-Fact PPF GROUP N.V. By: /s/ Lubomír Král Name: Lubomír Král Title: Attorney-in-Fact PPF BIOTECH B.V. By: /s/ Lubomír Král Name: Lubomír Král Title: Attorney-in-Fact 6

View Full Filing

View this SC 13D/A filing on SEC EDGAR